These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 38976164

  • 1. A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer.
    Liang E, Beshara M, Sheng H, Huang XW, Roh JM, Laurent CA, Lee C, Delmerico J, Tang L, Lo JC, Hong CC, Ambrosone CB, Kushi LH, Kwan ML, Yao S.
    Breast Cancer Res Treat; 2024 Nov; 208(2):349-358. PubMed ID: 38976164
    [Abstract] [Full Text] [Related]

  • 2. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study.
    Yao S, Laurent CA, Roh JM, Lo J, Tang L, Hahn T, Ambrosone CB, Kushi LH, Kwan ML.
    Breast Cancer Res Treat; 2020 Feb; 180(1):187-195. PubMed ID: 31912328
    [Abstract] [Full Text] [Related]

  • 3. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [Abstract] [Full Text] [Related]

  • 4. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X, Servitja S, Peña MJ, Prieto-Alhambra D, Nadal R, Mellibovsky L, Albanell J, Diez-Perez A, Tusquets I.
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [Abstract] [Full Text] [Related]

  • 5. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M.
    Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
    [Abstract] [Full Text] [Related]

  • 6. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
    Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, Harvey NC, Kanis JA.
    Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
    [Abstract] [Full Text] [Related]

  • 7. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
    [Abstract] [Full Text] [Related]

  • 8. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group.
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, de Ramon M, Díez-Pérez A, Albanell J, Tusquets I.
    Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R, Body JJ, DeCensi A, Reginster JY, Piscitelli P, Brandi ML, European Society for Clinical and Economical aspects of Osteoporosis and Osteoarthritis (ESCEO).
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study.
    Garnero P, Munoz F, Sornay-Rendu E, Delmas PD.
    Bone; 2007 Mar; 40(3):716-22. PubMed ID: 17112798
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B, Kirmaz C, Aydin K, Kafesciler SO, Guclu F, Hekimsoy Z.
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE.
    Cancer Treat Rev; 2008 Sep; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.